Kiora Pharmaceuticals (KPRX) Other financing activities (2015 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Other financing activities came in at $170.0 in Q1 2026, up 100.06% on a QoQ basis from -$265359.0 in Q4 2025.
Kiora Pharmaceuticals (KPRX) Other financing activities (2015 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 12 years of Other financing activities data on file, last reported at $170.0 in Q1 2026.
- Quarterly Other financing activities changed N/A year-over-year to $170.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $170.0 (up 100.0% YoY) and the FY2024 annual result came in at $1.7 million, up 744.67% from the prior year.
- Other financing activities grew to $170.0 in Q1 2026, from -$265359.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $15.0 million in Q1 2024 to a low of -$13.3 million in Q3 2024.
- A 5-year average of $547719.4 and a median of $265359.0 in 2025 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2024 — Other financing activities jumped 4925.13% — and 2025, when it fell 11.55%.
- Tracing KPRX's Other financing activities over 5 years: stood at $2.7 million in 2022, then slumped by 103.6% to -$98500.0 in 2023, then plunged by 13412.21% to -$13.3 million in 2024, then soared by 98.01% to -$265359.0 in 2025, then jumped by 100.06% to $170.0 in 2026.
- The last three Other financing activities figures came in at $170.0 (Q1 2026), -$265359.0 (Q4 2025), and $265359.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.20 Bn | 131.35 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.09 Bn | 78.10 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn |
| 4 | Moderna | 59.04 Bn | 53.90 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.04 Bn | 36.94 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.04 Bn | 9.65 Bn | 668.28 Mn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.50 Bn | - |
| 10 | Kiora Pharmaceuticals | 16.25 Mn | 16.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.00 Mn |
| Jun 30, 2026 | 5.00 Mn |
| Mar 31, 2026 | 170.00 |
| Mar 31, 2026 | 170.00 |
| Dec 31, 2025 | -265,359.00 |
| Dec 31, 2025 | -265,359.00 |
| Jun 30, 2025 | 265,359.00 |
| Jun 30, 2025 | 265,359.00 |
| Sep 30, 2024 | -13.31 Mn |
| Sep 30, 2024 | -13.31 Mn |
| Jun 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 300,000.00 |
| Mar 31, 2024 | 15.00 Mn |
| Mar 31, 2024 | 15.00 Mn |
| Jun 30, 2023 | -98,500.00 |
| Jun 30, 2023 | -98,500.00 |
| Mar 31, 2023 | 298,500.00 |
| Mar 31, 2023 | 298,500.00 |
| Dec 31, 2022 | 2.74 Mn |
| Dec 31, 2022 | 2.74 Mn |